Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769379 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,014
- Enrollment target
NCT00769379: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00769379 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,014 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00769379, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,014 participants
- Enrollment target
Study Summary
This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
Interventions
- OTHER Laboratory Biomarker Analysis
- RADIATION Whole Breast Irradiation
- BIOLOGICAL Trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,014 participants |
| Start Date | 2008-12-10 |
| Est. Completion | 2025-06-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769379
The ClinicalTrials.gov registry entry for NCT00769379 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,014 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00769379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00769379 about?
NCT00769379 is a clinical study titled "Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy". This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability o...
What is the current status of trial NCT00769379?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,014 participants. The study started on 2008-12-10. Estimated completion is 2025-06-02.
What interventions are being tested in trial NCT00769379?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Whole Breast Irradiation (RADIATION), Trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00769379?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.